Stock listing

Dusseldorf:87S Roivant Sciences Ltd. Aktie

German listing (Dusseldorf) of Roivant Sciences Ltd. · home listing NASDAQ:ROIV

Follow Roivant Sciences Ltd. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ROIV

$38.66 USD -0.07 (-0.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ROIV

Past year +90.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$38.46 – $39.51 USDNov 20, 2026
Volume
3.97M sharesNov 20, 2026
Market cap
$27.92B USDAt the close on Nov 20, 2026 · price × 722.3M shares outstanding
52-week range
$19.96 – $42.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$302.1M USDMedian day 6.40M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Roivant Sciences Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ROIV · Home$38.66 USD-0.075 (-0.2%)3,969,952$38.86$39.51$38.46$38.73Close on Nov 20, 2026
Frankfurt:87S€34.64 EUR+0.07 (+0.2%)—€35.02€35.11€34.64€34.57Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ROIV · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$38.66-0.075-0.2%$38.86$39.51$38.463,969,952
$38.73+0.02+0.1%$38.47$39.24$38.293,724,434
$38.71+0.10+0.3%$38.38$38.74$37.398,472,616
$38.61-0.92-2.3%$39.46$40.17$38.468,730,615
$39.53-0.46-1.2%$39.82$39.82$39.167,194,650
$39.99-1.86-4.4%$41.39$41.50$39.978,742,996
$41.85+0.66+1.6%$41.47$42.24$40.927,980,943
$41.19+0.52+1.3%$40.60$41.37$39.8810,589,897
$40.67+1.79+4.6%$39.56$41.43$39.2212,243,314
$38.88+2.26+6.2%$36.86$39.08$36.6212,263,945
$36.62-1.61-4.2%$38.23$38.27$36.4410,176,967
$38.23+2.19+6.1%$36.62$38.52$35.7110,911,067
$36.04+0.15+0.4%$35.89$36.78$35.566,686,435
$35.89-1.02-2.8%$36.95$37.29$35.825,699,508
$36.91-0.61-1.6%$37.50$37.94$36.784,574,470
$37.52+0.41+1.1%$37.44$37.97$37.293,728,780
$37.11+0.57+1.6%$36.43$37.13$36.165,477,394
$36.54+0.49+1.4%$36.04$36.83$35.806,567,877
$36.05-0.44-1.2%$36.66$36.91$35.669,868,526
$36.49-0.96-2.6%$37.18$37.42$36.368,225,400
$37.45+0.65+1.8%$36.68$38.49$36.6813,451,200
$36.80+1.88+5.4%$38.15$38.49$35.9916,839,600
$34.92+0.22+0.6%$35.00$35.52$34.383,670,500
$34.70+1.17+3.5%$33.78$35.14$33.606,334,300
$33.53-0.51-1.5%$34.12$34.12$33.234,923,400
$34.04+0.42+1.2%$33.82$34.36$33.704,565,900
$33.62+0.27+0.8%$33.14$34.09$33.004,293,700
$33.35-1.24-3.6%$34.44$34.92$33.266,322,200
$34.59-0.85-2.4%$34.92$35.41$34.554,732,100
$35.44+1.23+3.6%$34.24$35.59$34.155,533,200
$34.21-0.54-1.6%$34.28$34.56$33.326,403,900
$34.75-0.78-2.2%$35.22$35.49$34.635,738,800
$35.53-0.25-0.7%$35.86$36.34$34.755,737,700
$35.78+0.06+0.2%$35.98$36.33$35.256,200,500
$35.72+0.22+0.6%$35.61$36.00$35.194,365,800
$35.50-1.07-2.9%$36.35$36.79$35.443,272,000
$36.57+0.07+0.2%$36.77$36.96$36.235,282,400
$36.50-0.48-1.3%$37.03$37.35$35.756,587,600
$36.98+1.18+3.3%$35.65$37.25$35.286,970,800
$35.80-0.33-0.9%$35.98$36.19$35.526,764,400
$36.13-0.69-1.9%$36.64$36.75$35.915,659,500
$36.82-1.40-3.7%$38.00$38.47$36.789,272,900
$38.22-0.77-2.0%$38.73$39.17$38.116,752,500
$38.99-0.78-2.0%$39.02$39.90$38.725,620,100
$39.77-0.21-0.5%$40.11$40.71$39.7232,196,300
$39.98+0.41+1.0%$40.45$40.97$39.507,604,000
$39.57+0.07+0.2%$39.77$40.45$39.176,181,200
$39.50-1.52-3.7%$41.14$41.14$39.228,104,600
$41.02+0.20+0.5%$40.64$41.60$40.447,592,500
$40.82-0.12-0.3%$41.22$41.83$40.515,963,900
$40.94-0.87-2.1%$41.27$41.41$40.226,534,000
$41.81+0.33+0.8%$41.39$42.28$41.0811,147,100
$41.48+6.55+18.8%$39.98$42.50$38.4124,662,900
$34.93+0.52+1.5%$34.20$35.15$33.885,237,900
$34.41+0.23+0.7%$34.35$34.43$33.676,859,200
$34.18-0.34-1.0%$34.64$35.04$33.436,196,100
$34.52-0.12-0.3%$34.64$34.95$34.266,905,900
$34.64-0.07-0.2%$34.83$35.34$34.0239,466,600
$34.71-2.87-7.6%$37.01$37.13$34.698,765,000
$37.58+0.83+2.3%$36.85$37.81$36.504,920,800
$36.75+0.28+0.8%$36.93$36.93$36.325,260,300
$36.47+0.11+0.3%$36.82$37.29$36.314,481,403
$36.36+0.06+0.2%$36.22$36.57$35.715,117,294
$36.30-0.54-1.5%$37.03$37.18$36.236,185,500
$36.84-0.56-1.5%$36.91$37.55$36.683,127,800
Ticker
Dusseldorf:87S
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Roivant Sciences Ltd. news

Roivant Sciences Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 115 in all · newest Nov 10, 2026 · oldest 2021
Calls
21 calls with a replay · 21 with a transcript · latest Nov 9, 2026
Decks
22 decks · latest Nov 9, 2026

Where Roivant Sciences Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:ROIV · Home listingNASDAQUnited StatesUSD
gettex:87SgettexGermanyEUR
LS Exchange:A3C4MSLS ExchangeGermanyEUR
Tradegate:87STradegateGermanyEUR
BX Swiss:ROIVBX SwissSwitzerlandCHF
Lang & Schwarz:A3C4MSLang & SchwarzGermanyEUR
BOATS:ROIVBOATSUnited StatesUSD
Dusseldorf:87S · This pageDusseldorfGermanyEUR
Frankfurt:87SFrankfurtGermanyEUR
Munich:87SMunichGermanyEUR
Stuttgart:87SStuttgartGermanyEUR

Valuation

EV/sales 580× against a median of 8.1×: the highest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$23.82B USD
P/E
Loss
EV/sales
580×
EV/EBITDA
Negative EBITDA
Price/book
7.0×
Gross margin
88.7%
Operating margin
Revenue too small
Net margin
−838.2%
Debt to equity
0.0×
Beta vs S&P 500
1.00

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Roivant Sciences Ltd. · NASDAQ:ROIVUS$27.92BUS$23.82Bn/a580×n/a7.0×−838.2%0.0×1.00
CSL Limited · ASX:CSLUS$62.67BUS$72.05Bn/a4.6×14.3×4.2×−16.4%0.7×n/a
Biogen Inc. · NASDAQ:BIIBUS$36.89BUS$42.88B106×4.2×n/a1.9×3.4%0.4×0.34
Genmab A/S · OMXCOP:GMABUS$31.30BUS$34.64B42.9×8.1×24.4×4.9×17.0%0.8×n/a
Insmed Incorporated · NASDAQ:INSMUS$31.01BUS$30.41Bn/a20.0×n/a42.7×−39.9%0.8×0.01
Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNYUS$19.26BUS$15.68B7.3×n/an/a5.3×n/a0.0×0.58
Ascendis Pharma A/S · NASDAQ:ASNDUS$16.73BUS$16.15B17.1×12.2×61.1×10.0×73.5%0.3×0.49
Exelixis, Inc. · NASDAQ:EXELUS$15.77BUS$14.88B17.8×6.0×n/a8.6×35.4%0.0×0.69
Neurocrine Biosciences, Inc. · NASDAQ:NBIXUS$15.24BUS$14.50B21.7×3.9×n/a3.9×19.0%0.0×0.79
PharmaEssentia Corp. · TWSE:6446US$15.10BUS$14.39B65.3×22.9×56.4×13.5×36.8%0.0×n/a
BridgeBio Pharma, Inc. · NASDAQ:BBIOUS$14.86BUS$15.95Bn/a16.9×n/an/a−59.8%n/a0.89
Median of the othersUS$18.00BUS$16.05B21.7×8.1×40.4×5.3×17.0%0.3×0.58

Forecasts

9 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
50.36 USD · Analysts' mean
EPS, year to Mar 2027
-1.56 · 3 analysts
Revenue, year to Mar 2027
51.67M · 9 analysts

Team and board

Officers

OfficerRole
Eric VenkerRoivant President and Immunovant CEO
Richard PulikChief Financial Officer
Frank TortiVant Chair & President
Mayukh SukhatmePresident & Chief Investment Officer
Stephanie Lee GriffinChief Operating Officer, Roivant Platforms
Sam KaplanGeneral Counsel
Alex GasnerEVP, Roivant Health
Eric ValeurVice President, Head of Drug Discovery
Iván Cornella-TaracidoVice President of Translational Chemical Biology
Jason ImbriglioVice President, Discovery Chemistry
Tudor OpreaVice President, Translational Informatics
Huafeng XuChief Technology Officer
Ian RosenblumChief Information Officer
Jenni HumesChief Accounting Officer
Kelly GraffHead of People
Vivek RamaswamyFounder

Board

DirectorRole
Ilan OrenCompensation Committee Member, Nominating, Governance Committee Member
James MomtazeeNominating and Governance Committee Member
Keith Manchester M.D.Audit Committee Member
Meghan FitzgeraldAudit Committee Member, Nominating and Governance Committee Member
Melissa EpperlyAudit Committee Member

Events

Calls

CallWhenStatus
Roivant Sciences (NASDAQ:ROIV) Q2 2026 Earnings CallMon, Nov 09, 2026 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q1 2026 Earnings CallThu, Aug 06, 2026 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q4 2025 Earnings CallWed, May 20, 2026 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q3 2025 Earnings CallFri, Feb 06, 2026 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q2 2025 Earnings CallMon, Nov 10, 2025 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q1 2025 Earnings CallMon, Aug 11, 2025 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q4 2024 Earnings CallThu, May 29, 2025 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q2 2024 Earnings CallTue, Nov 12, 2024 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q1 2024 Earnings CallThu, Aug 08, 2024 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q4 2023 Earnings CallThu, May 30, 2024 · 8:00 AM ETReplay
All 21 calls
CallWhenStatus
Roivant Sciences (NASDAQ:ROIV) Q3 2024 Earnings CallTue, Feb 13, 2024 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q3 2023 Earnings CallTue, Feb 13, 2024 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q2 2023 Earnings CallMon, Nov 13, 2023 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q1 2023 Earnings CallMon, Aug 14, 2023 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q4 2022 Earnings CallWed, Jun 28, 2023 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q3 2022 Earnings CallMon, Feb 13, 2023 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q2 2022 Earnings CallMon, Nov 14, 2022 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q1 2022 Earnings CallMon, Aug 15, 2022 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q4 2021 Earnings CallTue, Jun 28, 2022 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q3 2021 Earnings CallMon, Feb 14, 2022 · 8:00 AM ETReplay
Roivant Sciences (NASDAQ:ROIV) Q2 2021 Earnings CallWed, Nov 17, 2021 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q2 2027Nov 9, 2026 · Before open+4.6%
Q1 2027Aug 6, 2026 · Before open+1.5%
Q4 2026May 20, 2026 · Before open+14.9%
Q3 2026Feb 6, 2026 · Before open+22.1%
Q2 2026Nov 10, 2025 · Before open+2.7%
Q1 2026Aug 11, 2025 · Before open−2.8%
Q4 2025May 29, 2025+3.5%
Q3 2025Feb 10, 2025 · Before open−0.9%
Q2 2025Nov 12, 2024 · Before open−1.4%
Q1 2025Aug 8, 2024 · Before open+6.7%
All 20 quarters
QuarterResultsShare move
Q4 2024May 30, 2024 · Before open−3.2%
Q3 2024Feb 13, 2024 · Before open−0.6%
Q2 2024Nov 13, 2023 · Before open+2.7%
Q1 2024Aug 14, 2023 · Before open+1.2%
Q4 2023Jun 28, 2023 · Before open+11.3%
Q3 2023Feb 13, 2023 · Before open+1.8%
Q2 2023Nov 14, 2022 · Before open+2.5%
Q1 2023Aug 15, 2022 · Before open−2.8%
Q4 2022Jun 28, 2022 · Before open+0.4%
Q3 2022Feb 14, 2022 · Before open+5.1%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings44 slidesNov 9, 2026
Corporate Update (August 2026)Corporate update27 slidesAug 28, 2026
Q1 2026 Earnings PresentationEarnings22 slidesAug 6, 2026
Q3 2025 Earnings PresentationEarnings32 slidesFeb 6, 2026
Investor Day (December 2025)Investor day192 slidesDec 11, 2025
Q2 2025 Earnings PresentationEarnings31 slidesNov 10, 2025
Technical Presentation (September 2025)Technical32 slidesSep 17, 2025
Technical Presentation (September 2025)Technical23 slidesSep 3, 2025
Q1 2025 Earnings PresentationEarnings25 slidesAug 11, 2025
Technical Presentation (March 2025)Technical36 slidesMar 19, 2025
All 22 decks
DeckKindSlidesDate
Merger or Acquisition (September 2024)Merger or acquisition8 slidesSep 18, 2024
FY2024 Earnings PresentationEarnings33 slidesMay 30, 2024
J.P. Morgan Healthcare Conference 2024Conference21 slidesJan 8, 2024
Corporate Update (November 2023)Corporate update27 slidesNov 28, 2023
Investor Presentation (November 2023)Investor deck93 slidesNovember 2023
Technical Presentation (September 2023)Technical23 slidesSep 26, 2023
Technical Presentation (June 2023)Technical25 slidesJune 2023
Investor Presentation (September 2022)Investor deck21 slidesSep 28, 2022
Investor Day (March 2022)Investor day86 slidesMar 30, 2022
Investor Day (September 2021)Investor day131 slidesSep 28, 2021
SPAC Merger (June 2021)SPAC merger114 slidesJun 25, 2021
SPAC Merger (May 2021)SPAC merger95 slidesMay 3, 2021

Open Decks

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue8.26M29.1M32.7M31.5M55.3M23.8M67.7M2.32M
Cost of revenue1.28M911.0K1.60M3.03M8.97M2.06M1.13M606.0K
Gross profit6.97M28.1M31.1M28.5M46.3M21.7M66.6M1.72M
Research and development681.8M550.4M439.9M454.1M483.0M236.6M263.2M513.0M
Selling, general and administrative610.5M591.4M687.4M600.5M775.0M259.9M335.8M237.2M
Operating income-515.1M-1.00B4.50B-906.8M-1.35B-1.07B-532.4M-748.5M
Depreciation and amortization3.35M14.1M22.0M18.9M5.93M5.93M5.93M748.5M
EBITDA-511.7M-989.2M4.52B-887.9M-1.35B-1.06B-526.5M0
Interest expense34.8M28.0M7.04M2.81M7.68M7.54M
Income before tax-264.6M-681.6M4.57B-885.0M-923.7M-898.5M-561.0M-807.2M
Income tax133.3M48.2M21.5M4.08M369.0K1.69M7.12M2.62M
Net income-299.8M-172.0M4.35B-1.01B-845.3M-809.2M1.20B-1.04B
Earnings per share, basic-0.43-0.245.55-1.42-1.26-1.281.75-4.84
Earnings per share, diluted-0.54-0.245.23-1.42-1.26-1.28

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents1.42B2.72B6.49B1.68B2.06B2.06B2.19B849.6M
Short-term investments2.87B2.17B05.01M13.6M77.7M
Receivables789.8M3.99M30.4M3.88M11.2M15.3M11.0M
Inventory35.3M2.76M063.9M1
Current assets5.17B5.00B6.73B1.80B2.15B2.19B2.22B1.19B
Property, plant and equipment12.0M12.1M15.3M39.1M25.9M14.7M73.9M11.1M
Total assets5.71B5.44B7.22B2.39B2.59B2.59B2.48B1.39B
Accounts payable18.0M23.7M14.0M37.8M34.6M20.6M10.3M6.23M
Current liabilities281.2M149.4M266.8M272.4M184.4M219.0M92.1M211.3M
Long-term debt430.6M375.5M210.0M170.3M
Total debt107.4M100.2M430.6M375.5M210.0M170.3M180.9M143.2M
Total liabilities416.3M249.7M774.0M782.0M523.7M527.7M368.4M450.5M
Shareholders' equity4.53B4.69B5.97B1.16B1.66B1.80B2.03B937.3M
Shares outstanding720.4M695.9M806.7M760.1M695.0M651.6M684.8M215.4M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-750.3M-839.5M-765.3M-843.4M-677.7M-552.1M-761.8M-1.02B
Capital spending-8.21M-4.60M-1.38M-12.7M-17.4M-5.81M-4.92M-11.4M
Free cash flow-758.6M-844.0M-766.6M-856.1M-695.2M-557.9M-766.7M-1.04B
Cash from investing-682.3M-1.77B5.20B-44.3M303.3M-31.7M1.69B-57.6M
Cash from financing134.2M-1.22B419.4M499.5M306.8M456.3M217.2M767.0M
Dividends paid-6.00M-162.7M
Share buybacks-319.5M-1.29B00-113.0K-1.19B-7.38M
Change in cash-1.29B-3.82B4.86B-381.9M-67.6M-127.6M1.34B1.12B

Open Financials

Filings

FilingDateTypeFiled with
3 · Initial statement of ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedNov 13, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedNov 13, 2026Other filingsSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedNov 10, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedNov 10, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedNov 10, 2026Other filingsSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
144 · Notice of proposed saleOct 28, 2026Other filingsSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
8-K · Current reportOct 21, 2026Current reportSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 5, 2026Big-stake noticeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleSep 30, 2026Other filingsSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
8-K · Current reportSep 18, 2026Meeting outcomeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
8-K · Current reportSep 8, 2026Current reportSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
144 · Notice of proposed saleAug 28, 2026Other filingsSEC
8-K · Current reportAug 28, 2026Current reportSEC
8-K · Current reportAug 27, 2026Current reportSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 20, 2026Other filingsSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
ARS · Annual report to shareholdersJul 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialJul 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementJul 29, 2026Meeting noticeSEC
144 · Notice of proposed saleJul 27, 2026Other filingsSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
144 · Notice of proposed saleMay 22, 2026Other filingsSEC
S-8 · Registration statement for employee plansMay 20, 2026Offer documentSEC
10-K · Annual reportMay 20, 2026Annual reportSEC
8-K · Current reportMay 20, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
144 · Notice of proposed saleApr 20, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedApr 16, 2026Other filingsSEC
144 · Notice of proposed saleApr 16, 2026Other filingsSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
144 · Notice of proposed saleApr 8, 2026Other filingsSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
8-K · Current reportApr 2, 2026ResultsSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
144 · Notice of proposed saleMar 26, 2026Other filingsSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
8-K/A · Current report, amendedMar 23, 2026Material contractSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
144 · Notice of proposed saleMar 17, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 6, 2026Big-stake noticeSEC
8-K · Current reportMar 3, 2026Material contractSEC
8-K · Current reportMar 3, 2026Current reportSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 19, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 9, 2026Other filingsSEC
10-Q · Quarterly reportFeb 6, 2026Quarterly reportSEC
8-K · Current reportFeb 6, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
144 · Notice of proposed saleJan 12, 2026Other filingsSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
144 · Notice of proposed saleDec 31, 2025Other filingsSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
144 · Notice of proposed saleDec 23, 2025Other filingsSEC
144 · Notice of proposed saleDec 23, 2025Other filingsSEC
144 · Notice of proposed saleDec 23, 2025Other filingsSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
144/A · Notice of proposed sale, amendedDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 12, 2025Big-stake noticeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
8-K · Current reportDec 11, 2025Current reportSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Roivant Sciences Ltd.’s releases

Common shares
722,323,015
Fully diluted
722,323,015

Fully diluted

LineShares
Common shares722,323,015

Share count over time

CountShares
Nov 22, 2026722,323,015

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity85.6MUS$3.13BSep 30, 2026
BlackRock61.9MUS$2.26BSep 30, 2026
Vanguard49MUS$1.79BSep 30, 2026
Morgan Stanley38.6MUS$1.41BSep 30, 2026
QVT Financial LP23.7MUS$868MSep 30, 2026
State Street22.4MUS$819MSep 30, 2026
Farallon Capital Management, L.L.C.21.7MUS$795MSep 30, 2026
UBS17.9MUS$655MSep 30, 2026
Geode Capital12.5MUS$468MSep 30, 2026
Jennison Associates LLC12.1MUS$441MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Adage Capital Partners Gp, L.L.C.11MUS$402MSep 30, 2026
Invesco9.14MUS$334MSep 30, 2026
JPMorgan8.3MUS$304MSep 30, 2026
Patient Square Capital LP7.71MUS$282MSep 30, 2026
Rubric Capital Management LP7.48MUS$274MSep 30, 2026
Assenagon Asset Management S.A.7.38MUS$270MSep 30, 2026
Two Seas Capital LP7.33MUS$268MSep 30, 2026
Bank of America7.23MUS$264MSep 30, 2026
Viking Global Investors LP6.76MUS$247MSep 30, 2026
Darwin Global Management, Ltd.6.75MUS$247MSep 30, 2026
Perceptive Advisors LLC6.51MUS$238MSep 30, 2026
Nearwater Capital Markets, Ltd5.6MUS$205MSep 30, 2026
AQR Capital Management LLC5.34MUS$194MSep 30, 2026
Dimensional4.96MUS$181MSep 30, 2026
Point72 Asset Management, L.P.4.82MUS$176MSep 30, 2026
Northern Trust4.66MUS$170MSep 30, 2026
Janus Henderson4.44MUS$163MSep 30, 2026
T. Rowe Price4.27MUS$156MSep 30, 2026
Goldman Sachs4.19MUS$153MSep 30, 2026
Pictet Asset Management Holding SA4.17MUS$153MSep 30, 2026
Baker Bros. Advisors LP3.66MUS$134MSep 30, 2026
BNY3.31MUS$121MSep 30, 2026
Affinity Asset Advisors, LLC3.2MUS$117MSep 30, 2026
ADAR1 Capital Management, LLC3.08MUS$113MSep 30, 2026
Manufacturers Life Insurance Company, The2.89MUS$106MSep 30, 2026
Citigroup Inc2.78MUS$102MSep 30, 2026
D. E. Shaw & Co., Inc.2.54MUS$92.9MSep 30, 2026
Woodline Partners LP2.51MUS$91.7MSep 30, 2026
Maverick Capital LTD2.31MUS$84.4MSep 30, 2026
Wellington2.03MUS$74.2MSep 30, 2026
Integral Health Asset Management, LLC2MUS$18.3MSep 30, 2026
Franklin Templeton2MUS$73.7MSep 30, 2026
Schwab1.94MUS$71MSep 30, 2026
Lord, Abbett & Co. LLC1.89MUS$69.2MSep 30, 2026
Nuveen1.77MUS$64.8MSep 30, 2026
Candriam S.C.A.1.7MUS$62.3MSep 30, 2026
Legal & General1.65MUS$60.3MSep 30, 2026
Daiwa Securities Group Inc.1.55MUS$56.7MSep 30, 2026
Gotham Asset Management, LLC1.52MUS$55.7MSep 30, 2026
Penn Davis McFarland Inc1.52MUS$55.7MSep 30, 2026

This page holds 50 of 511 holders. Open Shareholders

Funds

HolderSharesValueAs of
Fidelity Growth Company Fund22.5MUS$675MMay 31, 2026
Vanguard Total Stock Market Index Fund16MUS$566MJun 30, 2026
iShares Core S&P Mid-Cap ETF15.4MUS$546MJun 30, 2026
Vanguard Small-Cap Index Fund11.5MUS$409MJun 30, 2026
Vanguard Small-Cap Growth Index Fund6.66MUS$236MJun 30, 2026
Fidelity Growth Company K6 Fund6.22MUS$187MMay 31, 2026
Growth Portfolio5.28MUS$187MJun 30, 2026
Invesco S&P MidCap Momentum ETF5.22MUS$177MJul 31, 2026
Fidelity Series Growth Company Fund5.2MUS$156MMay 31, 2026
Vanguard Extended Market Index Fund5.17MUS$183MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
iShares Biotechnology ETF3.66MUS$130MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF3.5MUS$124MJun 30, 2026
Fidelity Contrafund3.25MUS$115MJun 30, 2026
Vanguard Explorer Fund2.97MUS$101MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.2.37MUS$84MJun 30, 2026
Fidelity Extended Market Index Fund2.32MUS$69.5MMay 31, 2026
State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF2.28MUS$80.8MJun 30, 2026
Fidelity Mid-Cap Stock Fund2.08MUS$70.4MJul 31, 2026
iShares Russell Mid-Cap ETF2.01MUS$71.1MJun 30, 2026
Select Biotechnology Portfolio1.98MUS$59.5MMay 31, 2026
Morgan Stanley Discovery Portfolio1.92MUS$68MJun 30, 2026
Fidelity Mid Cap Index Fund1.85MUS$62.9MJul 31, 2026
Transamerica Capital Growth1.65MUS$55.9MJul 31, 2026
Morgan Stanley Insight Fund1.6MUS$56.5MJun 30, 2026
iShares S&P Mid-Cap 400 Growth ETF1.56MUS$55.4MJun 30, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund1.38MUS$46.7MJul 31, 2026
Select Health Care Portfolio1.28MUS$38.4MMay 31, 2026
Discovery Portfolio1.24MUS$44MJun 30, 2026
Schwab U.S. Mid-Cap ETF1.22MUS$36.6MMay 31, 2026
Dimensional U.S. Core Equity 2 ETF1.17MUS$39.5MJul 31, 2026
Vanguard Health Care Index Fund1.13MUS$33.8MMay 31, 2026
iShares Russell 1000 Value ETF1.09MUS$38.7MJun 30, 2026
PGIM Jennison Health Sciences Fund1.02MUS$30.7MMay 29, 2026
Schwab U.S. Large-Cap Growth ETF966KUS$29MMay 31, 2026
iShares S&P Mid-Cap 400 Value ETF949KUS$33.6MJun 30, 2026
PGIM Jennison Small Company Fund865KUS$30.6MJun 30, 2026
U.S. Core Equity 2 Portfolio862KUS$29.2MJul 31, 2026
Fidelity Total Market Index Fund858KUS$25.7MMay 31, 2026
Growth Portfolio839KUS$29.7MJun 30, 2026
Fidelity Blue Chip Growth Fund819KUS$27.8MJul 31, 2026
Fidelity Advisor Biotechnology Fund777KUS$26.3MJul 31, 2026
iShares Russell Mid-Cap Value ETF752KUS$26.6MJun 30, 2026
Vanguard S&P Mid-Cap 400 Index Fund719KUS$21.6MMay 31, 2026
Fidelity Contrafund K6705KUS$24.9MJun 30, 2026
Fidelity Series Total Market Index Fund689KUS$20.7MMay 31, 2026
Goldman Sachs Small/Mid Cap Growth Fund645KUS$19.3MMay 31, 2026
Fidelity Advisor Health Care Fund640KUS$21.7MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF594KUS$21MJun 30, 2026
Invesco BuyBack AchieversTM ETF583KUS$19.8MJul 31, 2026
PGIM Jennison Mid-Cap Growth Fund571KUS$17.1MMay 29, 2026

This page holds 50 of 419 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
QVT Financial LP
Other: Director by Deputization
Sale798USD 38.24US$30,516Nov 17, 2026
QVT Financial LP
Other: Director by Deputization
Sale75,716USD 38.24US$2.9MNov 17, 2026
QVT Financial LP
Other: Director by Deputization
Sale525,507USD 38.24US$20.1MNov 17, 2026
Gold Daniel Allen
Director
Sale798USD 38.24US$30,516Nov 17, 2026
Gold Daniel Allen
Director
Sale75,716USD 38.24US$2.9MNov 17, 2026
Gold Daniel Allen
Director
Sale525,507USD 38.24US$20.1MNov 17, 2026
Manchester Keith S
Director
Sale798USD 38.24US$30,516Nov 17, 2026
Manchester Keith S
Director
Sale75,716USD 38.24US$2.9MNov 17, 2026
Manchester Keith S
Director
Sale525,507USD 38.24US$20.1MNov 17, 2026
QVT Financial LP
Other: Director by Deputization
Sale79,461USD 39.17US$3.11MNov 16, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
QVT Financial LP
Other: Director by Deputization
Sale550,280USD 39.17US$21.6MNov 16, 2026
QVT Financial LP
Other: Director by Deputization
Sale18,927USD 38.99US$738KNov 16, 2026
QVT Financial LP
Other: Director by Deputization
Sale131,073USD 38.99US$5.11MNov 16, 2026
Gold Daniel Allen
Director
Sale79,461USD 39.17US$3.11MNov 16, 2026
Gold Daniel Allen
Director
Sale550,280USD 39.17US$21.6MNov 16, 2026
Gold Daniel Allen
Director
Sale18,927USD 38.99US$738KNov 16, 2026
Gold Daniel Allen
Director
Sale131,073USD 38.99US$5.11MNov 16, 2026
Manchester Keith S
Director
Sale79,461USD 39.17US$3.11MNov 16, 2026
Manchester Keith S
Director
Sale550,280USD 39.17US$21.6MNov 16, 2026
Manchester Keith S
Director
Sale18,927USD 38.99US$738KNov 16, 2026
Manchester Keith S
Director
Sale131,073USD 38.99US$5.11MNov 16, 2026
Pulik Richard
Officer: CFO
Sale45,195USD 41.47US$1.87MNov 11, 2026
Pulik Richard
Officer: CFO
Sale82,170USD 42.03US$3.45MNov 11, 2026
Pulik Richard
Officer: CFO
Sale47,635USD 41.89US$2MNov 11, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale158,194USD 40.44US$6.4MNov 10, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale29,749USD 41.00US$1.22MNov 10, 2026
Pulik Richard
Officer: CFO
Sale125,000USD 41.20US$5.15MNov 10, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale200,000USD 36.31US$7.26MNov 3, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale200,000USD 36.59US$7.32MOct 28, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale185,856USD 35.09US$6.52MOct 20, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale14,144USD 35.42US$501KOct 20, 2026
Epperly Melissa B,
Director
Sale16,850USD 36.08US$608KOct 1, 2026
Epperly Melissa B,
Director
Sale900USD 36.57US$32,913Oct 1, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale200,000USD 36.62US$7.32MSep 30, 2026
Fitzgerald Meghan
Director
Sale4,712USD 39.68US$187KSep 15, 2026
Fitzgerald Meghan
Director
Sale400USD 40.45US$16,180Sep 15, 2026
Epperly Melissa B,
Director
Sale4,338USD 39.65US$172KSep 15, 2026
Epperly Melissa B,
Director
Sale600USD 40.38US$24,228Sep 15, 2026
Fitzgerald Meghan
Director
Sale20,000USD 39.90US$798KSep 8, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale166,182USD 35.63US$5.92MAug 28, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale33,818USD 36.44US$1.23MAug 28, 2026
Sukhatme Mayukh
Director, Officer: President & CIO
Sale144,756USD 36.48US$5.28MAug 21, 2026
Sukhatme Mayukh
Director, Officer: President & CIO
Sale17,519USD 37.30US$653KAug 20, 2026
Sukhatme Mayukh
Director, Officer: President & CIO
Sale172,899USD 37.17US$6.43MAug 19, 2026
Sukhatme Mayukh
Director, Officer: President & CIO
Sale105,141USD 36.59US$3.85MAug 18, 2026
Sukhatme Mayukh
Director, Officer: President & CIO
Sale31,801USD 37.18US$1.18MAug 18, 2026
Sukhatme Mayukh
Director, Officer: President & CIO
Sale284,707USD 36.25US$10.3MAug 17, 2026
Sukhatme Mayukh
Director, Officer: President & CIO
Sale243,177USD 36.23US$8.81MAug 14, 2026
Venker Eric
Officer: President & Immunovant CEO
Sale200,000USD 34.95US$6.99MJul 27, 2026
Fitzgerald Meghan
Director
Sale10,000USD 34.90US$349KJun 30, 2026

This page holds 50 of 76 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
FMR LLC11.80%85.6MSep 30, 2026Schedule 13G
BlackRock, Inc.8.20%59.3MSep 30, 2026Schedule 13G
Morgan Stanley5.70%40.7MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Eric Venker
Other companies: Immunovant, Inc. (Chief Executive Officer · Since at least Feb 18, 2020); Arbutus Biopharma Corporation (Director · Feb 18, 2020 – Feb 18, 2020 · Past); Sio Gene Therapies Inc (Director · Feb 17, 2020 – Feb 17, 2020 · Past)
Roivant President and Immunovant CEO · Since at least Oct 1, 2021
Andrew Lo
Other companies: AbCellera Biologics Inc. (Director · Since at least Dec 3, 2021); BridgeBio Pharma, Inc. (Director · Since at least Jun 23, 2020)
Director · Oct 1, 2021 – Sep 15, 2022 · Past
James Momtazee
Other companies: BridgeBio Pharma, Inc. (Director · Since at least Jun 27, 2019); PRA Health Sciences Inc (Director · Aug 13, 2019 – Jul 1, 2021 · Past)
Nominating and Governance Committee Member · Since at least Oct 1, 2021
Rakhi Kumar
Other companies: Amanat Acquisition Corp (Director · Since at least May 18, 2026); NeuroPace, Inc. (Director · Since at least Jun 7, 2024)
Chief Accounting Officer · Oct 24, 2023 – Feb 20, 2025 · Past
Frank Torti
Other companies: Immunovant, Inc. (Director · Since at least Apr 1, 2025)
President and Vant Chair · Since at least Jul 29, 2025
Frank Torti
Other companies: Immunovant, Inc. (Executive Chairman · Since at least Apr 9, 2026)
Vant Chair & President · Since at least May 20, 2026
Matthew Gline
Other companies: Arbutus Biopharma Corporation (Director · Since at least Feb 24, 2025)
CEO, Director · Since at least Oct 1, 2021
Meghan Fitzgerald
Other companies: Tenet Healthcare Corporation (Director · Since at least May 7, 2021)
Audit Committee Member, Nominating and Governance Committee Member · Since at least Mar 13, 2023
Alex GasnerEVP, Roivant Health · Since at least Nov 4, 2026
Eric ValeurVice President, Head of Drug Discovery · Since at least Nov 4, 2026
All 27 people
PersonSeat
Huafeng XuChief Technology Officer · Since at least Nov 4, 2026
Ian RosenblumChief Information Officer · Since at least Nov 4, 2026
Ilan OrenCompensation Committee Member, Nominating, Governance Committee Member · Since at least Apr 17, 2026
Iván Cornella-TaracidoVice President of Translational Chemical Biology · Since at least Nov 4, 2026
Jason ImbriglioVice President, Discovery Chemistry · Since at least Nov 4, 2026
Jennifer HumesChief Accounting Officer · Since at least Feb 19, 2025
Jenni HumesChief Accounting Officer · Since at least Sep 22, 2026
Keith Manchester M.D.Audit Committee Member · Since at least Jun 25, 2025
Kelly GraffHead of People · Since at least Nov 4, 2026
Matt GlineAug 27, 2026 – Oct 30, 2026 · Past
Mayukh SukhatmePresident & Chief Investment Officer · Since at least Dec 17, 2025
Melissa EpperlyAudit Committee Member · Since at least Oct 27, 2026
Richard PulikChief Financial Officer · Since at least Mar 28, 2025
Sam KaplanGeneral Counsel · Since at least Nov 4, 2026
Stephanie Lee GriffinChief Operating Officer, Roivant Platforms · Since at least Nov 5, 2026
Tudor OpreaVice President, Translational Informatics · Since at least Nov 4, 2026
Vivek RamaswamyFounder · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Roivant Sciences Ltd.